Discovery/R&D

  1. Leaving The Incubator With Kavitha Iyer Rodrigues 6/28/2020

    A strategic departure from the biotech incubator requires the coordination of moving parts aplenty. Development timelines, seed funding, facilities development, and team dynamics are just a sampling of the critical aspects. It's a move multi-time founder and Zumutor Biologics CEO Kavitha Iyer Rodrigues is well-versed in. Iyer Rodrigues joins us with lessons learned from her time in those trenches.

  2. The AAV Vector Challenge With Selecta's Dr. Carsten Brunn 1/12/2021

    The Business of Biotech kicks off our Cell & Gene Miniseries with Dr. Carsten Brunn, President & CEO at Selecta Biosciences. Guest host Erin Harris, chief editor at cellandgene.com, joins us for a discussion on Selecta's ImmTOR platform and how the company is addressing the immunogenicity of adeno-associated virus (AAV) vectors challenge faced by gene therapy companies.

  3. Topical Ocular Biologics with Claris Bio's Clarke Atwell 6/30/2024

    Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, Claris Bio is rewriting the ophthalmology rulebook. CEO Clarke Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if successful in the clinic, its Neurotrophic Keratitis candidate will vastly improve the patient experience. Atwell joins this episode of the Business of Biotech. Listen now!

  4. Med Device Meets Biopharma With OncoSec's Dan O'Connor, J.D. 5/17/2021

    OncoSec CEO & Director Dan O'Connor, J.D. joins the Business of Biotech to discuss his company's development of proprietary application and injection technologies for direct delivery of its pipeline of immunotherapeutic candidates and combination therapies into the tumor environment. O'Connor shares leadership lessons gleaned from his service as a Captain in the United States Marine Corps during Operation Desert Shield, and how he's applied those lessons as his company charts the manufacturing and regulatory challenges along its unique development timeline.

  5. Dr. Gaurav Shah: Rocket's Chief Gene Therapist & Virtuoso 8/30/2020

    Rocket Pharmaceuticals CEO Dr. Gaurav Shah shares the parallels between his leadership in the gene therapy space and his successes as a Grammy®-nominated recording artist with the Business of Biotech podcast. This episode is full of actionable insight on the inspiration behind how Dr. Shah manages the science and process side of the business, his employees, financing, and stakeholder expectations by drawing from his passion for—and understanding of—music.

  6. High-Throughput Discovery With BIOPTIC's Andrey Dobry 1/19/2025

    Andrey "Dobry" Doronichev, the innovator who made YouTube mobile, is now revolutionizing biotech with his startup, BIOPTIC. In this episode of The Business of Biotech, Dobry explains how AI and advanced screening are reshaping drug discovery. Learn more about BIOPTIC’s bold vision, the challenges of data access, and overcoming skepticism in the biotech industry.

  7. Expanding The Proteome with ProFound's John Lepore, M.D. 7/28/2024

    Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question:  What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome.

  8. Lipid Nanoparticle Gene Coding With SalioGen Therapeutics' Ray Tabibiazar, M.D. 3/14/2022

    This episode of the Business of Biotech is fire. In fact, it's an interview with SalioGen Therapeutics Chairman and CEO Ray Tabibiazar, M.D.,, whose last name \_literally translates\_ to "Dr. Fire." Learn how he got that name, what's shaped his technology-agnostic philosophy on therapeutic development, the advantages of a genome engineering technology that leverages proprietary mammal-derived enzymes, rather than viruses, and how SalioGen is possibly carrying forth a pipeline that's 15 candidates deep and addressing eye, liver, heart, lung, bone marrow, and kidney diseases.

  9. Celyad CEO Filippo Petti On In-House Allogeneic Cell Therapy Manufacturing 2/8/2021

    Join Matt Pillar and Erin Harris as we catch up with Celyad Oncology chief Filippo Petti on his company's differentiated approach to the discovery and development of allogeneic CAR-T cell therapy candidates for the treatment of cancer. Petti shares the technology and how the company intends to scale in-house manufacturing in its Belgium-based manufacturing facility.

  10. ML-Enabled Drug Discovery With LabGenius' James Field, Ph.D. 7/6/2023

    We explore the intersection of tech and bio with Dr. James Field, founder and CEO of LabGenius. If you're concerned with what ML will do to — or for — your biopharma business, don't miss this episode